Compare ATRO & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATRO | TWST |
|---|---|---|
| Founded | 1968 | 2013 |
| Country | United States | United States |
| Employees | 2620 | N/A |
| Industry | Military/Government/Technical | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.0B |
| IPO Year | N/A | 2018 |
| Metric | ATRO | TWST |
|---|---|---|
| Price | $76.24 | $57.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $86.00 | $46.88 |
| AVG Volume (30 Days) | 448.3K | ★ 1.1M |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $376,572,000.00 |
| Revenue This Year | $14.92 | $18.91 |
| Revenue Next Year | $8.81 | $15.07 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 20.32 |
| 52 Week Low | $19.90 | $23.30 |
| 52 Week High | $83.96 | $59.00 |
| Indicator | ATRO | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 60.54 | 65.15 |
| Support Level | $70.72 | $41.85 |
| Resistance Level | $76.98 | $57.88 |
| Average True Range (ATR) | 3.04 | 3.26 |
| MACD | 1.14 | 0.91 |
| Stochastic Oscillator | 96.19 | 82.49 |
Astronics Corp supplies products to the aerospace, defense, and electronics industries. The company has two reportable segments namely Aerospace and Test Systems. The aerospace segment serves three primary markets: military, commercial transport, and General Aviation. The Test Systems segment serves the aerospace, defense, and semiconductor markets. The company generates a majority of its revenue from the Aerospace segment. Geographically, it generates a majority of its revenue from the United States.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.